Systemic sclerosis is a chronic autoimmune disease in which abnormalities of small blood vessels, immune activation, and excessive connective-tissue deposition produce variable injury to the skin and internal organs. Its characteristic hardening of the skin gives rise to the name scleroderma, from Greek words meaning “hard skin.” However, the disease is not confined to the skin: the lungs, gastrointestinal tract, heart, and kidneys can be affected, sometimes before extensive skin changes become apparent.
The defining biological processes are vascular dysfunction, autoimmunity, and fibrosis. Their relative importance differs between organs and between individuals. Raynaud phenomenon, in which fingers or toes change color during episodes of reduced blood flow, is frequently an early manifestation. Subsequent disease may remain predominantly vascular and cutaneous or develop into substantial internal-organ involvement. Clinical assessment therefore combines the distribution and evolution of skin changes with disease-specific antibodies and systematic evaluation of organ function.
Systemic sclerosis is uncommon but carries substantial risks of disability and premature death. Advances in the recognition of pulmonary vascular disease, treatment of kidney crises, and therapies for lung fibrosis have changed its clinical course. It nevertheless remains a heterogeneous condition without a single treatment that reverses all its manifestations.
Clinical forms and terminology
Systemic sclerosis belongs to the group of systemic autoimmune connective-tissue diseases. The term scleroderma is sometimes used interchangeably with systemic sclerosis, but it also encompasses localized disorders, particularly morphea, that have a different clinical course. Localized scleroderma can involve skin and underlying tissues without the characteristic systemic vasculopathy and visceral disease of systemic sclerosis. The distinction is therefore more than a matter of how much skin is affected.
The two principal cutaneous subsets are limited cutaneous systemic sclerosis and diffuse cutaneous systemic sclerosis. In limited cutaneous disease, skin thickening remains distal to the elbows and knees, although the face may also be involved. In diffuse cutaneous disease, thickening extends proximal to the elbows or knees and may involve the trunk. These categories describe anatomical distribution rather than a simple distinction between mild and severe disease. Limited cutaneous disease can cause life-threatening pulmonary vascular or gastrointestinal complications, while the course of diffuse disease varies considerably.
Diffuse cutaneous disease often develops with a relatively short interval between Raynaud phenomenon and other manifestations. Skin thickening may progress rapidly during the first few years, and clinically important lung, cardiac, or renal complications can occur early. Limited cutaneous disease more often follows years of Raynaud phenomenon and may accumulate vascular complications over a longer period. These are population-level patterns, not fixed sequences that apply to every person.
The historical acronym CREST denotes calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia. Sclerodactyly means thickening and tightening of the fingers; telangiectasias are visibly dilated small blood vessels. CREST describes a recognizable constellation commonly associated with limited cutaneous disease, but not every feature must be present, and the acronym does not capture the full range of internal-organ involvement. Contemporary classification generally favors the limited and diffuse cutaneous terminology.
A small minority of patients have systemic sclerosis sine scleroderma: characteristic vascular, serological, and internal-organ findings without clinically evident skin thickening. Others have overlap syndromes that combine systemic sclerosis with features of rheumatoid arthritis, inflammatory muscle disease, or systemic lupus erythematosus. These presentations demonstrate why skin findings alone cannot define the entire disease. Cutaneous subset, autoantibody profile, disease duration, and organ involvement each provide partly independent information about clinical phenotype.
Epidemiology, susceptibility, and historical recognition
Estimates of prevalence vary markedly with geography, population ancestry, ascertainment methods, and diagnostic definitions. Many population studies report prevalence in the tens to several hundreds of cases per million people, with annual incidence commonly measured in single digits to a few tens per million. Comparisons between studies require caution because hospital registries, administrative databases, and population-based surveys identify somewhat different groups. Wider recognition of early disease also changes the number of recorded cases.
Women are affected substantially more often than men, with female-to-male ratios commonly around 3:1 to 5:1, although estimates differ between populations. Onset is most frequent in adulthood, especially middle age, but childhood and late-life disease both occur. Men with systemic sclerosis have shown more severe organ involvement and poorer survival in several cohorts, despite the disease being less common among men. Ancestry-associated differences in age at onset, cutaneous subset, and organ complications have also been reported, but biological susceptibility cannot be separated neatly from environmental exposure, access to care, and other social determinants of health.
Systemic sclerosis is not usually inherited as a single-gene disorder. Familial aggregation and genetic association studies support a heritable component, but most patients have no affected close relative. Susceptibility loci include regions involved in antigen presentation and immune signaling, such as HLA class II, IRF5, and STAT4. Several associations overlap with those found in other autoimmune diseases. Genetic variation therefore appears to alter the probability and phenotype of disease rather than determine a uniform outcome.
Occupational exposure to respirable crystalline silica is associated with increased risk, particularly in some highly exposed workforces. Associations with certain organic solvents have also been reported, although exposure measurement and confounding complicate interpretation. Neither exposure is necessary for disease to develop. The interaction between inherited susceptibility, environmental injury, and immune responses remains incompletely resolved.
Descriptions recognizable as scleroderma appeared in European medical literature centuries before modern immunology; Carlo Curzio published a detailed account in 1753. During the twentieth century, recognition of vascular and visceral disease established that the condition was systemic rather than solely dermatological. Autoantibody testing, standardized skin scoring, pulmonary function testing, and modern imaging subsequently made it possible to distinguish clinically meaningful subgroups. The introduction of angiotensin-converting enzyme inhibitors for renal crisis in the late 1970s and the development of targeted pulmonary vascular therapies were major changes in the natural history of particular complications.
Vascular injury, immune activation, and fibrosis
The disease mechanism is commonly described as a triad of vasculopathy, immune dysregulation, and fibrosis. These processes interact rather than occurring in a single established sequence. Dysfunction of the vascular endothelium—the cellular lining of blood vessels—alters vascular tone, permeability, and communication with circulating immune cells. Increased vasoconstrictor signaling, including endothelin activity, coexists with impaired vasodilator responses. Repeated vascular injury is accompanied by narrowing of small arteries, capillary loss, and structurally abnormal attempts at repair.
Raynaud phenomenon reflects reversible vasospasm, but systemic sclerosis adds fixed structural vascular disease. Capillaries can become enlarged, hemorrhagic, and progressively depleted. Tissue oxygen delivery is consequently impaired, especially in the fingers, where cold exposure normally provokes vasoconstriction. The combination of abnormal vascular regulation and anatomical vessel loss helps explain why digital ulcers can recur and why restoring blood flow is more difficult than in uncomplicated primary Raynaud phenomenon.
Both innate and adaptive components of the immune system participate. Activated T cells, B cells, macrophages, and other immune populations produce mediators that influence vascular cells and connective tissue. Type I interferon-associated gene-expression patterns are found in subsets of patients. B-cell abnormalities include altered signaling and production of disease-associated autoantibodies. These antibodies are valuable clinical markers, although their presence does not establish that each directly causes the tissue injury associated with it.
Fibroblasts and myofibroblasts generate excessive extracellular matrix, including collagen. Transforming growth factor beta is a major profibrotic mediator; interleukin-6, platelet-derived growth factor, and other signaling pathways also contribute. Matrix accumulation thickens and stiffens tissues, while matrix remodeling and altered cell–matrix interactions can help sustain fibroblast activation. Epigenetic changes, cellular senescence, and mechanical feedback are active areas of investigation. Fibrosis is therefore not simply passive scar deposition after inflammation: it can become a persistent, self-reinforcing tissue state.
The relative contributions of these pathways differ by tissue and disease stage. Early edematous skin may contain substantial inflammatory activity, whereas longstanding gastrointestinal dysfunction may reflect smooth-muscle atrophy, neural abnormalities, and established fibrosis. Pulmonary arterial disease is dominated by vascular remodeling, while interstitial lung disease involves injury and remodeling of the lung interstitium. This biological diversity explains why an immune-directed treatment can improve one manifestation without controlling another, and why changes in blood markers do not always parallel changes in organ function.
Skin, peripheral circulation, and the musculoskeletal system
Skin involvement often begins with puffy fingers or hands, followed by progressive thickening and reduced flexibility. An early edematous phase may evolve into an indurated phase and later into softer but thinner or atrophic skin. Tightening over the fingers can reduce movement, while facial involvement may produce a smaller mouth opening and radial furrows around the lips. Pigmentary changes, itching, dryness, and altered sweating are also common. The severity of visible skin disease does not reliably reveal the severity of internal-organ involvement.
The modified Rodnan skin score is the standard clinical measure of skin thickness used in many trials and specialist assessments. An examiner palpates 17 body sites and assigns each a score from 0, indicating normal thickness, to 3, indicating severe thickening; the total ranges from 0 to 51. The score is most useful when performed consistently by trained examiners. It captures one important disease domain but does not directly measure fibrosis in internal organs, and its interpretation depends partly on disease duration and the natural evolution of skin thickening.
Peripheral vascular disease can produce painful fingertip ulcers, pitting scars, and tissue loss. Ulcers may arise from ischemia or from mechanical stress over tight skin and joint prominences. Severe ischemia can lead to gangrene, while secondary infection may complicate wound healing. Telangiectasias commonly occur on the face, hands, and mucosal surfaces. Their appearance reflects abnormal microvascular architecture rather than the inflammatory vessel-wall destruction characteristic of many forms of vasculitis.
Calcinosis consists of calcium-containing deposits in the skin or subcutaneous tissues, usually despite normal circulating calcium and phosphate concentrations. Deposits are often located at pressure points, including the fingers and elbows, and may cause discomfort, discharge, or recurrent local inflammation. Acro-osteolysis, or resorption of the distal finger bones, can occur in association with longstanding vascular and tissue injury. Neither calcinosis nor acro-osteolysis is explained by skin thickening alone.
Musculoskeletal manifestations include joint pain, inflammatory arthritis, tendon involvement, muscle weakness, and fixed contractures. Tendon friction rubs are palpable or audible grating sensations during movement and are associated particularly with more extensive disease. Weakness may reflect inflammatory myopathy, fibrosing muscle disease, deconditioning, malnutrition, or several factors together. Hand impairment has disproportionate effects on dressing, food preparation, work, and other daily tasks. Physical therapy and occupational therapy are consequently important components of care, although functional improvement does not necessarily imply reversal of the underlying vascular or fibrotic process.
Pulmonary and cardiac involvement
Interstitial lung disease is among the most important causes of systemic sclerosis-related morbidity and death. It results from injury and fibrosis in the supporting tissues of the lung and can reduce lung volume and gas transfer. Symptoms include exertional breathlessness and a persistent dry cough, although early disease may be asymptomatic. High-resolution computed tomography commonly shows a nonspecific interstitial pneumonia pattern, with ground-glass opacity, fine reticulation, and varying degrees of traction bronchiectasis. A usual interstitial pneumonia pattern occurs less frequently.
Pulmonary function testing characterizes physiological impairment and change over time. Forced vital capacity measures exhaled volume after maximal inspiration, while diffusing capacity for carbon monoxide reflects gas transfer across the alveolar–capillary interface. A falling forced vital capacity can indicate progressive restrictive disease, but no single result establishes progression by itself. Diffusing capacity may decrease because of interstitial disease, pulmonary vascular disease, or both. Imaging, symptoms, test quality, and other explanations therefore influence interpretation.
Pulmonary arterial hypertension is a separate major complication, caused by remodeling and narrowing of small pulmonary arteries. It increases the load on the right ventricle and can lead to right-sided heart failure. Pulmonary hypertension in systemic sclerosis can also result from extensive lung disease, left-heart dysfunction, or other mechanisms, making accurate classification essential. Right-heart catheterization establishes the hemodynamic diagnosis. Under contemporary definitions, precapillary pulmonary hypertension includes mean pulmonary arterial pressure above 20 mmHg, pulmonary arterial wedge pressure of 15 mmHg or less, and pulmonary vascular resistance above 2 Wood units; attribution to pulmonary arterial hypertension also requires clinical assessment of alternative causes.
Cardiac involvement may affect the myocardium, conduction system, pericardium, or coronary microcirculation. Recurrent microvascular ischemia and fibrosis can impair relaxation or contraction and create a substrate for rhythm disturbances. Manifestations range from asymptomatic imaging abnormalities to myocarditis, ventricular dysfunction, pericardial effusion, or clinically significant arrhythmia. Cardiac symptoms may overlap with those of lung disease, and preserved left-ventricular ejection fraction does not exclude important cardiac involvement.
Evaluation uses combinations of pulmonary function testing, echocardiography, electrocardiography, circulating cardiac markers, and selected advanced imaging. Cardiac magnetic resonance imaging can characterize ventricular function and patterns of myocardial injury or fibrosis. Screening for pulmonary arterial hypertension commonly combines echocardiographic findings with diffusing capacity, biomarkers, and clinical variables; algorithms such as DETECT apply to defined patient groups. A normal result at one assessment does not establish lifelong absence of cardiopulmonary disease, because pulmonary vascular and myocardial complications can emerge later.
Gastrointestinal and renal manifestations
The gastrointestinal tract can be affected from the mouth to the anus. Small oral aperture, dental difficulties, and reduced saliva can interfere with eating and oral care. In the esophagus, impaired peristalsis and a weak lower esophageal sphincter promote gastroesophageal reflux disease, regurgitation, and swallowing difficulty. Persistent reflux may cause esophagitis or stricture. Reflux and aspiration may coexist with pulmonary disease, although the extent to which treating reflux alters the course of lung fibrosis remains uncertain.
Gastric involvement includes delayed emptying, which can produce early satiety, bloating, and nausea. Gastric antral vascular ectasia, sometimes called “watermelon stomach” because of its endoscopic appearance, can cause chronic or overt bleeding and iron-deficiency anemia. In the small intestine, impaired motility permits bacterial overgrowth, with bloating, diarrhea, nutrient malabsorption, and weight loss. Severe dysmotility can cause intestinal pseudo-obstruction: symptoms and bowel dilation resembling mechanical obstruction without a physical blockage.
Colonic and anorectal disease can produce constipation, fecal incontinence, or both. The mechanisms include abnormal motility, altered sensation, and sphincter dysfunction. Gastrointestinal symptoms are therefore not a uniform syndrome, and diarrhea does not necessarily indicate excessive propulsion; it may arise from bacterial overgrowth or overflow around retained stool. Advanced disease can result in malnutrition, occasionally requiring enteral or parenteral nutritional support. Symptom burden can be substantial even when cardiopulmonary function remains relatively preserved.
Scleroderma renal crisis is an acute vascular complication characterized by rapidly developing kidney dysfunction, usually accompanied by abrupt or accelerated hypertension. The underlying lesions involve small renal arteries and arterioles, with intimal thickening, luminal narrowing, and ischemic activation of the renin–angiotensin–aldosterone system. Microangiopathic hemolysis and reduced platelet counts may occur. A minority of episodes occur without marked hypertension, which can delay recognition if the diagnosis is associated only with very high blood pressure.
Renal crisis occurs particularly in early diffuse cutaneous disease and is strongly associated with anti-RNA polymerase III antibodies. Exposure to higher doses of corticosteroids is an established clinical risk factor. Angiotensin-converting enzyme inhibitors transformed treatment and remain its central pharmacological intervention, but some patients still require dialysis, temporarily or permanently. Other causes of acute kidney injury, urinary abnormalities, and chronic kidney disease can occur independently or alongside systemic sclerosis. Not every decline in kidney function represents renal crisis, and the distinction has major implications for treatment.
Diagnosis, classification, and organ assessment
Diagnosis rests on the combined pattern of clinical findings, serology, and organ involvement rather than on a single definitive test. Raynaud phenomenon with puffy fingers, sclerodactyly, digital pitting, telangiectasias, or characteristic nailfold changes raises suspicion. Medical history establishes the timing of vascular and nonvascular manifestations, while physical examination determines skin distribution and looks for vascular, musculoskeletal, and internal-organ clues. In typical cases, a skin biopsy is unnecessary; its findings are not sufficiently specific to replace clinical assessment.
Antinuclear antibodies are present in most patients. More specific antibody patterns help characterize risk. Anticentromere antibodies are associated predominantly with limited cutaneous disease and pulmonary arterial hypertension. Anti-topoisomerase I antibodies, also called anti-Scl-70, are associated with interstitial lung disease and often with diffuse cutaneous involvement. Anti-RNA polymerase III antibodies are associated with rapidly progressive skin disease and renal crisis. These are statistical associations rather than guarantees: antibody-positive patients do not invariably develop the linked complication, and antibody-negative patients are not necessarily protected.
Nailfold capillaroscopy directly examines capillaries at the base of the fingernails. Giant capillaries, microhemorrhages, capillary loss, and disorganized new vessel formation can form a characteristic scleroderma pattern. These findings help distinguish secondary Raynaud phenomenon associated with connective-tissue disease from primary Raynaud phenomenon. Similar changes can occur in related disorders, including inflammatory muscle diseases, so capillaroscopy is interpreted alongside other evidence.
The 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria use a weighted score. Skin thickening of the fingers extending proximal to the metacarpophalangeal joints is sufficient on its own, scoring 9 points. Otherwise, points are assigned for finger changes, fingertip lesions, telangiectasia, abnormal nailfold capillaries, pulmonary arterial hypertension or interstitial lung disease, Raynaud phenomenon, and specified autoantibodies. A total of at least 9 points classifies systemic sclerosis when the criteria are applicable. These criteria standardize research populations and support clinical reasoning, but they are not a substitute for diagnosis in every early or atypical presentation.
The differential diagnosis includes localized scleroderma, eosinophilic fasciitis, scleredema, scleromyxedema, diabetic cheiroarthropathy, and nephrogenic systemic fibrosis. Absence of Raynaud phenomenon, sparing of the fingers, unusual distribution, relevant drug or exposure history, and distinctive laboratory or tissue findings may point elsewhere. After systemic sclerosis is identified, assessment extends beyond the most visible manifestation. Pulmonary function tests, chest imaging, cardiac evaluation, blood pressure, kidney function, and targeted gastrointestinal investigations establish the baseline pattern against which subsequent change is interpreted.
Treatment of vascular disease and organ-specific complications
Treatment is organized around the manifestation being treated, its severity, and the distinction between potentially reversible dysfunction and established structural damage. There is no single medication that controls all vascular, inflammatory, and fibrotic features. Multidisciplinary care commonly includes rheumatology, respiratory medicine, cardiology, nephrology, gastroenterology, dermatology, and rehabilitation services. The evidence supporting individual interventions ranges from large randomized trials to observational studies and expert consensus, particularly for uncommon complications.
For Raynaud phenomenon, dihydropyridine calcium-channel blockers such as nifedipine are widely used. Phosphodiesterase type 5 inhibitors and intravenous prostacyclin analogues are used in more severe peripheral vascular disease. Digital-ulcer management also addresses ischemia, pressure or trauma, infection, and wound care. Bosentan, an endothelin-receptor antagonist, reduces the development of new digital ulcers in appropriate patients but has not shown equivalent evidence for accelerating healing of existing ulcers. The distinction between preventing a new lesion and healing an established one is important when interpreting treatment outcomes.
Pulmonary arterial hypertension is treated with drugs directed at endothelin, nitric oxide–cyclic guanosine monophosphate, and prostacyclin pathways. Depending on disease severity and risk assessment, treatment may involve combinations rather than a single agent. Examples include endothelin-receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, and prostacyclin-receptor agonists. Pulmonary hypertension due primarily to left-heart disease or extensive interstitial lung disease is not automatically managed in the same way. Misclassification can expose patients to ineffective or harmful treatment.
Renal crisis requires urgent treatment centered on angiotensin-converting enzyme inhibition and management of its systemic consequences. Kidney function can initially worsen despite control of blood pressure, and renal recovery may occur after a prolonged period of dialysis. The effectiveness of these drugs in established crisis does not establish that giving them prophylactically prevents crisis. Cardiac arrhythmias, ventricular dysfunction, and inflammatory myocardial disease are managed according to their underlying mechanisms and severity, while accounting for the broader systemic disease.
Gastrointestinal treatment is similarly mechanism-specific. Proton-pump inhibitors suppress acid in reflux disease; prokinetic drugs address selected motility disorders; and antibiotics are used for small-intestinal bacterial overgrowth. Endoscopic therapy can control bleeding from gastric antral vascular ectasia. Nutritional assessment, dental care, and support for swallowing or bowel dysfunction address problems that drugs alone may not resolve. Rehabilitation can target hand function, mouth opening, endurance, and activities of daily living. These measures influence disability and health-related quality of life even when they do not alter measurable fibrosis.
Immunomodulatory, antifibrotic, and transplantation therapies
Disease-modifying treatment has increasingly focused on skin fibrosis and interstitial lung disease. Mycophenolate mofetil is widely used because clinical trials and subsequent experience support its role in these manifestations. Cyclophosphamide has also demonstrated benefit in systemic sclerosis-associated interstitial lung disease, but toxicity limits its duration and suitability. The Scleroderma Lung Study II, published in 2016, compared two years of mycophenolate with one year of oral cyclophosphamide followed by placebo. Both groups showed improvement in lung-function measures over the study period, while mycophenolate had better tolerability on several measures.
Nintedanib is an antifibrotic tyrosine kinase inhibitor that slows decline in forced vital capacity in systemic sclerosis-associated interstitial lung disease. In the 2019 SENSCIS trial, the adjusted annual rate of decline was approximately 52 mL with nintedanib and 93 mL with placebo, a difference of about 41 mL per year. This result represents slowing of functional deterioration, not restoration of normal lung tissue. Gastrointestinal adverse effects, especially diarrhea, were common. Many trial participants were also receiving mycophenolate, reflecting the use of antifibrotic and immune-directed treatment within the same disease setting.
Tocilizumab, an interleukin-6 receptor-blocking monoclonal antibody, has evidence for preservation of lung function in selected patients with early inflammatory disease. Its pivotal phase III trial did not meet the primary skin-score endpoint, but lung-function findings supported regulatory approval for systemic sclerosis-associated interstitial lung disease in the United States in 2021. Rituximab, which targets CD20-positive B cells, has evidence for improvement in skin disease and is also used in selected lung-disease settings. Regulatory approvals and the strength of evidence differ by country and indication.
Autologous hematopoietic stem-cell transplantation is an intensive option for carefully selected patients with severe, progressive disease. It uses immunoablative treatment followed by reinfusion of the patient’s previously collected hematopoietic stem cells. Randomized studies, including ASTIS and SCOT, demonstrated long-term benefits in selected populations compared with cyclophosphamide-based treatment. However, treatment-related mortality and serious cardiac, infectious, and other complications are substantial considerations. Eligibility depends heavily on organ reserve, disease trajectory, and the balance between immediate procedural risk and longer-term disease risk.
Immunosuppressive treatment introduces risks including cytopenias, infection, reproductive toxicity with some agents, and organ-specific adverse effects. Corticosteroids require particular caution because of their association with renal crisis, especially at higher doses. Investigational approaches include additional B-cell-directed treatments, antifibrotic pathway inhibitors, and cellular therapies. Small uncontrolled reports of major responses cannot establish comparative effectiveness or long-term safety. A randomized controlled trial can distinguish treatment effects from natural changes such as spontaneous softening of skin after an earlier period of progression.
Disease course, prognosis, and research challenges
The course of systemic sclerosis varies from slowly evolving vascular and gastrointestinal disease to rapidly progressive multisystem illness. Time since the first non-Raynaud manifestation is often used to describe disease duration because Raynaud phenomenon may precede other features by many years. Diffuse skin thickening commonly reaches its greatest extent early and may later soften, but improvement in skin does not prove that lung, vascular, or gastrointestinal disease has resolved. Different organs can follow different trajectories in the same individual.
Prognosis depends strongly on the nature and severity of internal-organ involvement. Interstitial lung disease and pulmonary arterial hypertension are major causes of disease-related death in contemporary cohorts. Primary cardiac disease and renal crisis remain important, while infection, malignancy, and other conditions also contribute to overall mortality. Survival estimates vary with cohort composition, starting point, access to treatment, and whether studies include mild or very early disease. A single survival percentage therefore cannot adequately describe all patients with systemic sclerosis.
Autoantibody profiles refine risk assessment but do not predict an individual course with certainty. Anti-RNA polymerase III-positive disease has also been associated with a close temporal relationship between systemic sclerosis onset and cancer in a subset of patients. Research has identified tumor alterations involving the relevant antigen in some such cases, supporting a possible cancer-triggered immune mechanism. This does not mean that all systemic sclerosis is caused by cancer or that every person with these antibodies has malignancy. The strength and clinical meaning of associations depend on antibody type, timing, and population.
Disability reflects more than organ failure. Hand stiffness, recurrent ulcers, gastrointestinal symptoms, altered appearance, fatigue, and chronic pain can restrict work, social participation, sleep, and self-care. Patient-reported outcomes capture burdens that lung-function tests and skin scores may miss. Sexual dysfunction, including erectile dysfunction, and difficulties affecting intimacy are also recognized. Studies that assess only a single organ endpoint can consequently overlook important changes in daily functioning.
Research increasingly seeks molecular subgroups that predict progression or response to treatment. Candidate biomarkers include circulating proteins, autoantibody profiles, skin gene-expression signatures, and quantitative imaging measures. Their usefulness depends on reproducibility and added predictive value beyond standard clinical assessment. Trial design remains difficult because systemic sclerosis is rare, biologically heterogeneous, and capable of natural improvement in some domains while worsening in others. Composite measures, longitudinal organ assessments, and patient-reported outcomes are used to address this complexity, but no single endpoint fully represents the disease.